Document Detail

Establishment of a novel cell line from intraductal papillary neoplasm of the bile duct.
MedLine Citation:
PMID:  24778022     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: Intraductal papillary neoplasm of the bile duct (IPNB) is a novel and increasingly-occurring disease. Its characteristics remain uncertain because of the lack of an in vitro culture system. We established and characterized a novel cell line from a human IPNB.
MATERIALS AND METHODS: We obtained tumor tissue from a surgical specimen from a patient with IPNB. Cells were primary co-cultured with mouse stromal cells in serum-free medium. Tumor characteristics were compared among the primary IPNB, established cell line, and xenograft.
RESULTS: We successfully established an IPNB cell line. We temporary termed this cell line Kobe Bile Duct Cancer (KBDC)-11. Xenograft formed a tumor which had ductal structures and mucus production as the primary tumor did. Overexpression of p53, MUC staining pattern, and CD133 expression were common among the primary IPNB, KBDC-11, and the xenograft.
CONCLUSION: This novel cell line established from IPNB exhibited the same features as IPNB and might contribute to studies of IPNB and its process of malignant transformation.
Sae Murakami; Tetsuo Ajiki; Yuichi Hori; Taro Okazaki; Takumi Fukumoto; Yonson Ku
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  34     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2014 May 
Date Detail:
Created Date:  2014-04-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  2203-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The real deal: using cytochalasin B in sonodynamic therapy to preferentially damage leukemia cells.
Next Document:  Differential Expression of Galectin-1 and Galectin-3 in Canine Non-malignant and Malignant Mammary T...